Assertio Announces Transfer of Listing from Nasdaq Global Select Market to Nasdaq Capital Market
Company Receives additional 180-day grace period, until
Trading on Nasdaq Capital Market is expected to begin on
The transfer of the Company’s listing to the Nasdaq Capital Market is not expected to have any impact on trading in the Company’s shares. Assertio’s shares will continue to trade uninterrupted under the symbol “ASRT.” The Nasdaq Capital Market is a continuous trading market that operates in substantially the same manner as the Nasdaq Global Select Market, and listed companies must meet certain financial and corporate governance requirements to qualify for continued listing.
On transfer to the Nasdaq Capital Market, Nasdaq granted the Company a second grace period of 180 calendar days, or until
The Company intends to continue to actively monitor the minimum bid price requirement and, as appropriate, will consider available options to resolve any deficiencies and regain compliance.
About
Investor Contact
lroth@burnsmc.com
ir@assertiotx.com
Forward Looking Statements
Statements in this communication that are not historical facts are forward-looking statements that reflect Assertio’s current expectations, assumptions and estimates of future performance and economic conditions. These forward-looking statements are made in reliance on the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements relate to, among other things, future events or the future performance or operations of
Source: Assertio Therapeutics, Inc.
(COMMON STOCK)
Minimum 15 minutes delayed.